This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Prognosis

Authoring team

The prognosis for patients with gastrointestinal carcinoid tumour is:

  • with no metastases - median survival 5-8 years
  • with metastases - median survival 38 months

Five-year survival rate of patients is approximately 75.1% in the stomach, 76.1% in the small intestine, 76.1% in the appendix, and 87.5% in the rectum (3)

Poor prognostic factors are (3):

  • carcinoid heart disease and high levels of tumor markers,
  • liver metastasis,
  • involvement of the thymus,
  • overexpression of the proliferation of Ki67,
  • mutation of the p53 gene

Reference:

  1. Endocr Relat Cancer. 2004 Mar;11(1):1-18.
  2. de Herder WW and Lamberts SWJ. Best Practice & Research Clinical Endocrinology & Metabolism 2004; Volume 18(4): 477-495.
  3. Gade AK, Olariu E, Douthit NT. Carcinoid Syndrome: A Review. Cureus. 2020 Mar 5;12(3):e7186. doi: 10.7759/cureus.7186.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.